Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ST-02
- Development stage
- Phase 3
- Lead developer
- Saillant Therapeutics
- Modality
- Small Molecules
- Administration
- Pyelocaliceal Instillation
01
Overview
ST-02 is a novel mucoadhesive suspension of gemcitabine, specifically formulated for pyelocaliceal instillation. It is being investigated for the local treatment of low-grade Upper Tract Urothelial Carcinoma (UTUC). This formulation allows for direct delivery of the chemotherapeutic agent, gemcitabine, to the upper urinary tract, enabling a localized and extended therapeutic effect.
- Other names
- mucoadhesive gemcitabine suspension for pyelocaliceal instillation
02
Targets
DNA
Beyond the preview
Go deeper on ST-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ST-02.